Boundless Bio, Inc. (BOLD)
- Previous Close
10.66 - Open
10.86 - Bid 10.94 x 100
- Ask 11.07 x 100
- Day's Range
10.03 - 11.21 - 52 Week Range
9.83 - 15.24 - Volume
158,692 - Avg. Volume
297,594 - Market Cap (intraday)
245.299M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by targeting extrachromosomal DNA. Its lead product candidate is BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. The company is also developing BBI-825, an oral inhibitor of ribonucleotide reductase, which is in Phase 1/2 clinical trial in cancer patients with resistance gene amplifications; and ecDTx 3 program targeting a kinesin involved with the cellular mechanism for segregation of ecDNA. Boundless Bio, Inc. was formerly known as Pretzel Therapeutics, Inc. and changed its name to Boundless Bio, Inc. in July 2019. The company was incorporated in 2018 and is headquartered in San Diego, California.
boundlessbio.comRecent News: BOLD
Compare To: BOLD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BOLD
Valuation Measures
Market Cap
245.30M
Enterprise Value
126.74M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-2.35
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.13%
Return on Equity (ttm)
-52.93%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-49.43M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
120.75M
Total Debt/Equity (mrq)
1.82%
Levered Free Cash Flow (ttm)
-30.95M